Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs in SARS-CoV-2 Induced ARDS
NCT04377334Phase 2Unknown
- Sponsor
- University Hospital Tübingen
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mesenchymal stem cells in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by University Hospital Tübingen. Primary endpoint: lung injury at day 10. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04377334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377334.